Goldman Sachs Alzheimer’s Disease Day — Infrastructure considerations: Outlook for blood-based testing

Below is a recording of the session titled: Infrastructure considerations: Outlook for blood-based testing as part of the Goldman Sachs Alzheimer’s Disease Day, held on October 3, 2023 in New York City. Dr. Joel Braunstein, CEO of C₂N Diagnostics, provides remarks on the outlook for blood-based testing for Alzheimer’s disease. Matt Sykes, Vice President of Goldman Sachs serves as moderator. 

Unlock the Session below.

Previous
Previous

Clinical Use of Blood Biomarkers in the Era of Disease Modifying Treatments for Early Symptomatic Alzheimer’s Disease

Next
Next

Diagnostic Tools & The New Blood Test